PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing new and improved biotherapeutics for the treatment of orphan diseases, with an initial focus on cardiopulmonary disorders.
Our proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which can lead to less frequent dosing and better patient compliance.
PhaseBio’s lead development candidate, PB1046, is a weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension (PAH); the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and X-linked dilated cardiomyopathy; and the treatment of cystic fibrosis.
We continue to explore opportunities to apply our ELP biopolymer technology to compounds that may benefit from its unique properties.
PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA.